Moderna Beats Q3 2026 Estimates as Revenue Rises 29% to $1.31B

Moderna (MRNA) beat estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $1.31 billion, up 29% from a year earlier, above the $890.3 million estimate, and adjusted EPS was $0.38 above the -$1.10 estimate.

Shares rose 3.0% in premarket trading as of 6:49 a.m. ET, to $248.75 from a $241.46 close.

Q3 2026 scorecard

By our calculation, revenue was $422.7 million above the estimate and adjusted EPS was $1.48 above it. The QoQ column compares with the previous quarter's revenue of $145.0 million and adjusted EPS of -$1.97. The YoY column compares with $1.02 billion and -$0.51 in the same quarter a year earlier.

Track record

• EPS record. Adjusted EPS beat the estimate in 8 of the last 8 reports, including this one.
• Revenue record. Revenue beat the estimate in 6 of the last 8 reports.
• Revenue trend. Revenue over the last 5 reports, oldest first: $1.02 billion, $678.0 million, $389.0 million, $145.0 million and $1.31 billion.

What to watch

• Next-quarter estimates. Consensus calls for EPS of -$1.73 and revenue of $675.4 million next quarter, based on 10 analysts.
• Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 29% increase to $1.31 billion.
• Estimate record. Whether Moderna extends a record of beating EPS estimates in 8 of its last 8 reports.
• Related coverage. See our reports on Atmus Filtration, Delek Logistics Partners, Delek US and Brookdale Senior Living.

Sources: Results are from Moderna's Nov. 6, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Moderna's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.